世界の抗ウイルス治療薬市場：薬剤タイプ別、流通チャネル別 - 成長、動向、予測

世界の抗ウイルス治療薬市場は2018～2023年にかけCAGR6.2%となる見通しです。C型肝炎やHIV感染の拡大と、ウイルス感染症を患う患者数の増加により、北米が同市場を独占しています。

当レポートでは、世界の抗ウイルス治療薬市場について調査し、市場の概要と成長動向、競合動向、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響因子

第5章 市場概要

• 現在の市場シナリオ
• ポーターズファイブフォース分析

第6章 促進因子、阻害因子、機会、課題分析

• 促進因子
• 阻害因子
• 市場機会
• 課題

第6章 市場セグメンテーション

• 薬剤タイプ別
  • ヘルペス
  • 肝炎
  • HIV
  • インフルエンザ
  • その他
• 流通チャネル別
  • 院内薬局
  • 独立型薬局・ドラッグストア
  • オンライン薬局
• 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • 南米

第8章 競合環境

• 合併・買収
• 協定、連携、提携
• 新製品上市

第9章 主要企業

• AbbVie, Inc.
• Bristol-Meyrs Squibb Company
• Cipla, Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi
• その他

第10章 市場の将来

The anti-viral therapeutics market is expected to register a CAGR of 6.0%, over the forecast period. North America dominates the market, owing to the growing prevalence of hepatitis C and human immunodeficiency viruses (HIV) infections, coupled with the presence of a huge patient pool suffering from virally infectious diseases.

• In order to combat drug resistance, the combination of various anti-virals with different mechanisms of action is used. Combination antiviral therapy is the standard of care in HIV and hepatitis C virus infections, and it is likely to become increasingly used in other viral infections.
• Anti-viral therapeutics are commercially available for diseases, like influenza, hepatitis C, chickenpox, papilloma, and AIDS. Additionally, there is increasing adoption of nucleoside and nucleotide analogues as first-line anti-virals. Based on the current development pipeline, many small molecule-based anti-viral drugs (like interferons and other similar small protein analogues) are expected to receive their marketing approvals.

Key Market Trends

By Drug Type, HIV Anti-viral Drugs Mainly Boost the Global Market

HIV is a major global public health issue. According to the 2019 UNAIDS data, 24.5 million people were accessing antiretroviral therapy by the end of 2019. About 1.7 million people became newly infected with the virus in 2018. The vast majority of people living with HIV are located in low- and middle-income countries, with an estimated 66% living in Sub-Saharan Africa. However, the majority of HIV anti-viral consumption was exhibited in the North American region. Over the forecast period, the use of anti-virals in African countries is expected to increase multifold, as the majority of global companies are strategizing their HIV-based products in the emerging market.

North America is Expected to Dominate the Market over the Forecast Period

North America dominated the anti-viral therapeutics market, owing to the presence of well-established market players, as well as due to the growing prevalence of HIV and hepatitis C infections. The North American market is primarily driven by factors, such as the increasing occurrence of infectious diseases, increasing geriatric population base, and growing healthcare awareness, coupled with increasing healthcare expenditure in the region. However, there are limitations to market growth in the region, which include generic erosion and patent expiration of anti-viral drugs.

Competitive Landscape

The anti-viral therapeutics market is a fast-growing market. The current market share is majorly controlled by a few major pharmaceutical and biotechnology companies. There is a limited number of antiviral products in the market, and a large percentage of these drugs is expected to lose exclusivity in the coming future. This may be marked by the entry of generic manufacturers, expansion of market size, and lowering of market concentration.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
  • 4.2.2 Advancements in Molecular Biology Promoting Drug Development
  • 4.2.3 Growing Burden of HIV Infection
• 4.3 Market Restraints
  • 4.3.1 High Cost of Antiviral Drug Treatment
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Drug Type
  • 5.1.1 Herpes Anti-viral Drugs
  • 5.1.2 Hepatitis Anti-viral Drugs
  • 5.1.3 HIV Anti-viral Drugs
  • 5.1.4 Influenza Anti-viral Drugs
  • 5.1.5 Other Anti-viral Drugs
• 5.2 By Distribution Channel
  • 5.2.1 Hospital Pharmacy
  • 5.2.2 Independent Pharmacy and Drug Store
  • 5.2.3 Online Pharmacy
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 AbbVie Inc.
  • 6.1.2 Bristol-Meyrs Squibb Company
  • 6.1.3 Cipla Inc.
  • 6.1.4 F. Hoffmann-La Roche Ltd
  • 6.1.5 Gilead Sciences Inc.
  • 6.1.6 GlaxoSmithKline PLC
  • 6.1.7 Johnson & Johnson
  • 6.1.8 Merck & Co. Inc.
  • 6.1.9 Pfizer Inc.
  • 6.1.10 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS